SCHEMBL6890520

SCHEMBL6890520

Cc1cccc(OC(=O)OC(C)I)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.57
ALDH1A1 P00352 4/20 0.45
MAPT P10636 2/20 0.44
KMT2A Q03164 3/20 0.44
MAPK1 P28482 2/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ALOX5 P09917 1/20 0.43
POLB P06746 1/20 0.43
ACHE P22303 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
BCHE P06276 1/20 0.43
MEN1 O00255 1/20 0.43
PPARG P37231 1/20 0.43
FAAH O00519 1/20 0.42
CYP3A4 P08684 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6891334 0.84 MTNR1B (0.49) LMNAKMT2ABCHEMEN1
SCHEMBL6896351 0.83 MEN1 (0.39) LMNAALDH1A1MAPTKMT2AMAPK1
SCHEMBL819332 0.82 LMNA (0.74) LMNAALDH1A1MAPTKMT2AMAPK1
SCHEMBL29418226 0.82 LMNA (0.74) LMNAALDH1A1MAPTKMT2AMAPK1
SCHEMBL15984609 0.81 LMNA (0.54) LMNAALDH1A1MAPTKMT2AMAPK1
SCHEMBL6895672 0.81 ALDH1A1 (0.42) LMNAALDH1A1MAPTKMT2AALOX15
SCHEMBL410350 0.81 LMNA (0.67) LMNAALDH1A1MAPTKMT2AMAPK1
SCHEMBL15984583 0.80 LMNA (0.57) LMNAALDH1A1MAPTKMT2AMAPK1
SCHEMBL15984571 0.80 LMNA (0.57) LMNAALDH1A1MAPTKMT2AMAPK1
SCHEMBL6895467 0.80 LMNA (0.52) LMNAALDH1A1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 LMNA 2043/4885ALDH1A1 1161/4885MAPT 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.